163 related articles for article (PubMed ID: 10945505)
1. Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel.
Veitia R; David S; Barbier P; Vantard M; Gounon P; Bissery MC; Fellous A
Br J Cancer; 2000 Aug; 83(4):544-9. PubMed ID: 10945505
[TBL] [Abstract][Full Text] [Related]
2. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice.
Veitia R; Bissery MC; Martinez C; Fellous A
Br J Cancer; 1998 Oct; 78(7):871-7. PubMed ID: 9764577
[TBL] [Abstract][Full Text] [Related]
3. Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel.
Fromes Y; Gounon P; Veitia R; Bissery MC; Fellous A
J Protein Chem; 1996 May; 15(4):377-88. PubMed ID: 8819014
[TBL] [Abstract][Full Text] [Related]
4. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity.
Sun X; Li D; Yang Y; Ren Y; Li J; Wang Z; Dong B; Liu M; Zhou J
J Pathol; 2012 Mar; 226(4):666-73. PubMed ID: 21989536
[TBL] [Abstract][Full Text] [Related]
5. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel.
Nishio K; Arioka H; Ishida T; Fukumoto H; Kurokawa H; Sata M; Ohata M; Saijo N
Int J Cancer; 1995 Nov; 63(5):688-93. PubMed ID: 7591286
[TBL] [Abstract][Full Text] [Related]
6. Interaction of brain mitochondria with microtubules reconstituted from brain tubulin and MAP2 or TAU.
Jung D; Filliol D; Miehe M; Rendon A
Cell Motil Cytoskeleton; 1993; 24(4):245-55. PubMed ID: 8097434
[TBL] [Abstract][Full Text] [Related]
7. The scientific rationale for developing taxoids.
Aapro M
Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
[TBL] [Abstract][Full Text] [Related]
8. Stoichiometry of estramustine phosphate binding to MAP2 measured by the disassembly of chick brain MAP2:tubulin microtubules.
Burns RG
Cell Motil Cytoskeleton; 1990; 17(3):167-73. PubMed ID: 2125244
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel: a review of its pharmacology and clinical activity.
Trudeau ME
Can J Oncol; 1996 Jun; 6(1):443-57. PubMed ID: 8853517
[TBL] [Abstract][Full Text] [Related]
10. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.
Lee KM; Cao D; Itami A; Pour PM; Hruban RH; Maitra A; Ouellette MM
Histopathology; 2007 Oct; 51(4):539-46. PubMed ID: 17714470
[TBL] [Abstract][Full Text] [Related]
11. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
[TBL] [Abstract][Full Text] [Related]
12. Differential assembly kinetics of alpha-tubulin isoforms in the presence of paclitaxel.
Banerjee A; Kasmala LT
Biochem Biophys Res Commun; 1998 Apr; 245(2):349-51. PubMed ID: 9571153
[TBL] [Abstract][Full Text] [Related]
13. Deficient nucleation during co-polymerization of mammalian MAP2 and tobacco tubulin.
Hugdahl JD; Morejohn LC
Biochem Mol Biol Int; 1994 Sep; 34(2):375-84. PubMed ID: 7849649
[TBL] [Abstract][Full Text] [Related]
14. Unique functional characteristics of the polymerization and MAP binding regulatory domains of plant tubulin.
Hugdahl JD; Bokros CL; Hanesworth VR; Aalund GR; Morejohn LC
Plant Cell; 1993 Sep; 5(9):1063-80. PubMed ID: 8104575
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of docetaxel (Taxotere).
Lavelle F; Bissery MC; Combeau C; Riou JF; Vrignaud P; André S
Semin Oncol; 1995 Apr; 22(2 Suppl 4):3-16. PubMed ID: 7740328
[TBL] [Abstract][Full Text] [Related]
16. Identification of a new microtubule-interacting protein Mip-90.
González M; Cambiazo V; Maccioni RB
Eur J Cell Biol; 1995 Jun; 67(2):158-69. PubMed ID: 7664757
[TBL] [Abstract][Full Text] [Related]
17. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacology of docetaxel.
Bissery MC
Eur J Cancer; 1995; 31A Suppl 4():S1-6. PubMed ID: 7577097
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
